DIGITAL EDITIONS

Category: Acne

Formulation and Profile of FMX101 4% Minocycline Topical Foam for the Treatment of Acne Vulgaris

April 1, 2020

J Clin Aesthet Dermatol. 2020;13(4):14–21 by Leon Kircik, MD; James Q Del Rosso, DO; Jonathan S Weiss, MD; Vassilis Stakias, PharmD; Anat London, PhD; Rita Keynan; Yohan Hazot; Russell Elliott, PhD; and Iain Stuart, PhD Dr. Kircik is with the Icahn School of Medicine at Mount Sinai in New York, New York. Dr. Del Rosso

Efficacy of Topical Timolol 0.5% in the Treatment of Acne and Rosacea: A Multicentric Study

March 1, 2020

Background. Acne and rosacea are common chronic inflammatory skin diseases associated with psychosocial impairment, anxiety, depression, and impaired overall quality of life.

Influential Factors of Depression in Patients with Moderate and Severe Acne

February 1, 2020

J Clin Aesthet Dermatol. 2020;13(2)13–16 by Sherine Hosny Ahmed, MD; Amira Ahmed El-Kelish, MSc; Neveen Abdel Hafeez, MD; and Shewikare Taweek El-Bakry, MD All authors are with the Faculty of Medicine, Benha University in Benha, Egypt. FUNDING: No funding was provided for this study. DISCLOSURES: The authors have no conflicts of interest relevant to the

An Open-label, Phase IV Study Evaluating Lidose-isotretinoin Administered without Food in Patients with Severe Recalcitrant Nodular Acne: Low Relapse Rates Observed Over the 104-week Post-treatment Period

November 1, 2019

J Clin Aesthet Dermatol. 2019;12(11):13–18 by James Q. Del Rosso, MD; Linda Stein Gold, MD; Jeanett Segal; and Andrea L. Zaenglein, MD Dr. Del Rosso is with JDR Dermatology Research/Thomas Dermatology in Las Vegas, Nevada. Dr. Stein Gold is with the Department of Dermatology, Clinical Research Division at the Henry Ford Hospital in Detroit, Michigan. Dr.

Safety and Tolerability of Sarecycline for the Treatment of Acne Vulgaris: Results from a Phase III, Multicenter, Open-Label Study and a Phase I Phototoxicity Study

November 1, 2019

Objective. We sought to evaluate the safety, tolerability, and patterns of use for the once-daily oral, narrow-spectrum antibiotic sarecycline in patients with moderate-to-severe acne vulgaris during a 40-week Phase III, multicenter, open-label extension study.